Business Model Breakdown
How Kura Oncology Inc Makes Money
KURA
Market Cap
$684M
Annual Revenue
$83M
Profit Margin
-41.3%
Employees
192
The Short Version
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for cancer. Its primary business model revolves around the research, development, and commercialization of small-molecule therapeutics. Currently, its main revenue driver is KOMZIFTI (ziftomenib), an FDA-approved drug for relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). The company generates revenue by selling KOMZIFTI, and potentially through milestone payments and royalties from licensing agreements for its pipeline assets, such as the agreement with Kyowa Kirin for global rights ex-US. The business relies heavily on successful clinical trials, regulatory approvals, and effective commercialization of its oncology drugs.
Where the Revenue Comes From
KOMZIFTI product sales (primary and growing)
Licensing and collaboration revenue (e.g., Kyowa Kirin milestones and royalties)
Who buys: Oncology patients with specific genetic mutations (e.g., NPM1-mutant AML), typically prescribed by hematology-oncology specialists, and reimbursed by healthcare payers.
Why It Works (Competitive Advantages)
- ✔First-in-class FDA-approved menin inhibitor (KOMZIFTI) for NPM1-mutant AML
- ✔Strong intellectual property protecting ziftomenib
- ✔High market access quickly achieved post-approval
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs)
What Our Analysis Says
DVR Score as of April 10, 2026
Kura Oncology remains a highly speculative, high-risk, high-reward investment for 10x growth potential, with its core thesis centered on KOMZIFTI's market penetration. The Q4 2025 revenue of $17.34M, while higher than the previously reported early KOMZIFTI sales, still significantly missed the $74.52M consensus estimate, deepening concerns about commercialization execution. However, the initial market access for KOMZIFTI (84%) is positive, and the CEO's recent exercise of options (not selling) signals confidence, offsetting some negative sentiment from analyst PT cuts. The company maintains a robust cash position ($667.2M), providing a runway, but substantial cash burn and deep unprofitability persist. Future catalysts like H2 2026 combo data and long-term frontline sales potential provide upside, but the path requires robust KOMZIFTI sales ramp-up and successful clinical execution to validate its high valuation.